by Barry101 | May 16, 2022 | Press Release, Uncategorized
– First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer...
by Barry101 | May 12, 2022 | Press Release, Uncategorized
OCALA, Fla., May 12, 2022 — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
by Barry101 | Apr 21, 2022 | Press Release, Uncategorized
Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen’s anti-tumor potential is demonstrated with checkpoint blockade therapies in human clinical studies for...
by Barry101 | Apr 12, 2022 | Press Release, Uncategorized
– Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer – Company engages world-renowned CRO, Amarex Clinical Research LLC to conduct...
by Barry101 | Apr 11, 2022 | Press Release, Uncategorized
Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation (CKM) therapy, including Ampligen and pembrolizumab, successfully met primary endpoint Positive data from this proof-of-concept study demonstrate that short-term systemic CKM followed...
by Barry101 | Apr 11, 2022 | Press Release, Uncategorized
Primary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046) Data suggest that CKM regimen with Ampligen may be useful to enhance effectiveness of immunotherapies Data from clinical research conducted at Roswell Park...
